BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

finance.yahoo.com · 2026-09-12

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]

TickrTrends take: Ascendis Pharmaceuticals' resolution of its global patent dispute with BioMarin represents a reduction in litigation risk that removes a significant uncertainty hanging over the company. This type of legal clarity is typically important for valuation models, as it eliminates a contingent liability that could have materially affected future cash flows and competitive positioning. For investors tracking ASND's valuation status, this settlement provides the kind of resolved headwind that allows analysts to build more straightforward financial projections without having to account for potential adverse legal outcomes.

Read the full story at finance.yahoo.com →